中国肺癌杂志2018，Vol.21Issue(2)：110-115,6.DOI:10.3779/j.issn.1009-3419.2018.02.02
第三代EGFR-TKIs耐药之初探
Mechanisms of Resistance to the Third-generation Epidermal Growth Factor Receptor-Tyrosine Kinase Inhibitors in Non-small Cell Lung Cancer
倪莲芳 1聂立功2
作者信息
- 1. 100034 北京,北京大学第一医院老年内科
- 2. 100034 北京,北京大学第一医院呼吸和危重症科
- 折叠
摘要
Abstract
Targeted therapy of epidermal growth factor receptor tyrosine kinase inhibitor (EGFR-TKIs) has been the standard modality as first-line treatment of advanced EGFR-mutated non-small cell lung cancer(NSCLC).The third-generation EGFR-TKIs has been approved to overcome the EGFR T790M mutation in patients resistant to the first-or second-generation TKIs, which brings more survival benefits for patients with advanced NSCLC. Unfortunately, acquired resistance inevitably develops after application of approximately 10 months. Heterogeneities of the tumor determines the diversity of resistance.Mechanisms of resistance to the third-generation TKIs includs EGFR-dependent pathway(such as new EGFR mu-tations,T790M reduction/disappearance and EGFR amplification,etc.)and EGFR-independent pathway(such as bypass path-way activation and histological transformation,etc.).In this paper,we reviewed principle mechanisms of acquired resistance to third-generation EGFR-TKIs.关键词
EGFR受体/肺肿瘤/第三代EGFR-TKIs/耐药Key words
Epidermal growth factor receptor/Lung neoplasms/Third-generation tyrosine kinase inhibitors/Re-sistance引用本文复制引用
倪莲芳,聂立功..第三代EGFR-TKIs耐药之初探[J].中国肺癌杂志,2018,21(2):110-115,6.
